# Artiva Biotherapeutics

allogeneic NK (AB-101) — off-the-shelf cord-blood doses.

Source: https://en.bioecon.ru/companies/artiva-biotherapeutics/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $741.9 million in aggregate gross proceeds raised from inception through June 30, 2026 | https://www.stocktitan.net/sec-filings/ARTV/10-q-artiva-biotherapeutics-inc-quarterly-earnings-report-330c0f79d6d2.html |
| Capacity | capability to produce enough AlloNK to treat over 1,000 autoimmunity patients annually at current San Diego facility | https://s203.q4cdn.com/960442723/files/doc_presentations/2026/Mar/10/Artiva-Corporate-Deck_March-2026.pdf, https://www.artivabio.com/nk-cell-technology/ |
| Production site | 9,000 square-foot, cGMP-compliant cell production center in San Diego, California | https://www.artivabio.com/nk-cell-technology/, https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948ds1.htm |
| Regulatory approval | FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis | https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx, https://www.artivabio.com/nk-cell-therapy-pipeline/, https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948ds1.htm |
| Headcount | 106 employees as of March 31, 2026 | https://stockanalysis.com/stocks/artv/employees/ |
| Revenue | No revenue from product sales as of June 30, 2026 | https://www.stocktitan.net/sec-filings/ARTV/10-q-artiva-biotherapeutics-inc-quarterly-earnings-report-330c0f79d6d2.html |

Independent sources: investors.artivabio.com, s203.q4cdn.com, sec.gov, stockanalysis.com, stocktitan.net

## Technologies

- [NK-cell & CAR-NK therapy](https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/)